Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan.
about
CD4-specific designed ankyrin repeat proteins are novel potent HIV entry inhibitors with unique characteristicsProtective vaccination against papillomavirus-induced skin tumors under immunocompetent and immunosuppressive conditions: a preclinical study using a natural outbred animal modelTwo highly conserved cysteine residues in HPV16 L2 form an intramolecular disulfide bond and are critical for infectivity in human keratinocytesCutaneous and mucosal human papillomaviruses differ in net surface charge, potential impact on tropismThe Strong Protective Effect of Circumcision against Cancer of the PenisEfficacy of Carraguard-based microbicides in vivo despite variable in vitro activityDevelopment of AAVLP(HPV16/31L2) particles as broadly protective HPV vaccine candidateCurrent understanding of the mechanism of HPV infectionThe Interaction between Human Immunodeficiency Virus and Human Papillomaviruses in Heterosexuals in AfricaMultipurpose prevention technologies: the future of HIV and STI protectionThe cytoskeleton in papillomavirus infectionVaccination with human papillomavirus pseudovirus-encapsidated plasmids targeted to skin using microneedlesHuman papillomavirus type 16 entry: retrograde cell surface transport along actin-rich protrusionsLarge scale RNAi reveals the requirement of nuclear envelope breakdown for nuclear import of human papillomavirusesA Novel Microbicide/Contraceptive Intravaginal Ring Protects Macaque Genital Mucosa against SHIV-RT Infection Ex VivoEntry of human papillomavirus type 16 by actin-dependent, clathrin- and lipid raft-independent endocytosisConcatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccinesVLPs displaying a single L2 epitope induce broadly cross-neutralizing antibodies against human papillomavirusEstablishment of human papillomavirus infection requires cell cycle progressionDurable immunity to oncogenic human papillomaviruses elicited by adjuvanted recombinant Adeno-associated virus-like particle immunogen displaying L2 17-36 epitopesCapsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approachProduction of Furin-Cleaved Papillomavirus Pseudovirions and Their Use for In Vitro Neutralization Assays of L1- or L2-Specific AntibodiesA pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2Investigation of griffithsin's interactions with human cells confirms its outstanding safety and efficacy profile as a microbicide candidateCapsomer vaccines protect mice from vaginal challenge with human papillomavirusVirus movements on the plasma membrane support infection and transmission between cellsImmunogenicity of a trivalent human papillomavirus L1 DNA-encapsidated, non-replicable baculovirus nanovaccine.Clathrin- and caveolin-independent entry of human papillomavirus type 16--involvement of tetraspanin-enriched microdomains (TEMs)Identification of neutralizing conformational epitopes on the human papillomavirus type 31 major capsid protein and functional implicationsImmunogenic display of diverse peptides, including a broadly cross-type neutralizing human papillomavirus L2 epitope, on virus-like particles of the RNA bacteriophage PP7Potential anti-HPV and related cancer agents from marine resources: an overview.Impact of inhibitors and L2 antibodies upon the infectivity of diverse alpha and beta human papillomavirus types.Deciphering the Multifactorial Susceptibility of Mucosal Junction Cells to HPV Infection and Related Carcinogenesis.Research and application of marine microbial enzymes: status and prospects.Efficient Production of Papillomavirus Gene Delivery Vectors in Defined In Vitro Reactions.Mechanisms of cell entry by human papillomaviruses: an overview.The role of furin in papillomavirus infection.HPV16 infection of HaCaTs is dependent on β4 integrin, and α6 integrin processing.HUMAN PAPILLOMAVIRUS ASSOCIATION WITH HEAD AND NECK CANCERS: UNDERSTANDING VIRUS BIOLOGY AND USING IT IN THE DEVELOPMENT OF CANCER DIAGNOSTICSMeasurement of neutralizing serum antibodies of patients vaccinated with human papillomavirus L1 or L2-based immunogens using furin-cleaved HPV Pseudovirions.
P2860
Q21090521-60571BCC-377A-4F3C-85D9-F01BF7949408Q21131365-4FB85AF3-5E76-49B8-8BB8-3DB47E647139Q21143868-1669F4DF-DB69-4131-8A3E-EABB27E84EEDQ21245129-7D0BB819-09A3-40AC-A89E-E5F1C31D5DAAQ21296754-DADC7F17-AE79-4A80-A616-FC60692F414BQ21562543-9C5B3926-C9F2-42FC-B2D1-E019C28586C1Q24288709-4D8C63FB-A956-4463-B9C6-C7FB5C0C27FBQ24616134-A809096F-B571-4F3E-BF52-02A58D667020Q26799584-4A14CC9F-9A29-4812-849B-D37A4DBA4147Q26827796-739C579C-48C2-46C8-BB75-C308CF327B53Q26861667-31B518A7-49CB-4531-88BE-794BDBA88343Q27311290-9B8F29CA-CB08-47B6-BAD7-B4EEDD86BC32Q27318457-9C74A9D6-2132-439E-8CFB-8700B8E57ADEQ27325402-FD824D45-11EA-43F5-8485-951E81E7BCD3Q27334384-61CDA97B-BE96-485E-94D3-E84AF60A0011Q27346336-4B3B1288-421A-47C2-9D42-50B168A7F0DFQ28246307-ACA4D6B7-A28B-4C67-B620-CAB9AC76E10FQ28280059-950F23CA-C410-4D52-A617-89A4E4B3F32FQ28474811-C84E3CE9-74EC-4121-B636-C5934F818F2FQ28603888-B42CE30F-1BB1-40E6-AD40-3081B639270AQ28607775-2B01A11E-C98D-4A05-AF7B-6287A789759CQ28611356-02259675-E3B3-4F3F-AC63-61CA64FF79C3Q28741364-8457375E-78E5-447F-8C23-625A0EDA6152Q28741890-FC64C3F4-CB73-4E25-9969-2F6CA24DAE74Q28743261-54AC286B-BC93-45BC-9934-F20428ECD7D7Q30944807-160459B1-2E3F-4634-A36C-D3AF926F5182Q31159398-AF6B8A90-3438-4D63-9575-A18815AEAB34Q33374009-A37B79DA-A997-488F-9F4B-673C901E1F54Q33469751-B26E09C2-507D-45D9-B653-C12755D3DDD7Q33569555-CB130365-473D-47E0-A274-FE1B2BABA06BQ33575647-2801806B-ACB2-400F-A0E7-7B302386E710Q33591582-2BC19E12-0E98-44F7-AEDA-A5D04F53F406Q33613540-53B5F2B8-6E02-4DB8-8276-18A0DA625BDFQ33633062-0A5B6DDC-3218-4150-B7B2-240453A6CCAAQ33652425-45D95249-0F61-4049-AC48-8FC5335E8191Q33663169-5328BA82-FD89-4793-A58B-9C86920CE42FQ33693739-7C15AEF8-A3C2-4B34-940A-189939FCB6CDQ33714325-CCE97B2C-D536-4A12-9E09-75D0482111CBQ33805498-A782CFB7-9B2D-428E-9460-83DB0A39584CQ33856453-A5DA66ED-B572-452B-8367-A98AA4249E54
P2860
Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Genital transmission of HPV in ...... and inhibited by carrageenan.
@ast
Genital transmission of HPV in ...... and inhibited by carrageenan.
@en
Genital transmission of HPV in ...... and inhibited by carrageenan.
@nl
type
label
Genital transmission of HPV in ...... and inhibited by carrageenan.
@ast
Genital transmission of HPV in ...... and inhibited by carrageenan.
@en
Genital transmission of HPV in ...... and inhibited by carrageenan.
@nl
prefLabel
Genital transmission of HPV in ...... and inhibited by carrageenan.
@ast
Genital transmission of HPV in ...... and inhibited by carrageenan.
@en
Genital transmission of HPV in ...... and inhibited by carrageenan.
@nl
P2093
P356
P1433
P1476
Genital transmission of HPV in ...... and inhibited by carrageenan.
@en
P2093
Cynthia D Thompson
Douglas R Lowy
Jeffrey N Roberts
John T Schiller
Marcelino Bernardo
Peter L Choyke
Rhonda Kines
P2888
P304
P356
10.1038/NM1598
P407
P577
2007-07-01T00:00:00Z